Literature DB >> 344347

Effect of thymidine on activity of trimethoprim and sulphamethoxazole.

A Stokes, R W Lacey.   

Abstract

Thymidine at levels as low as 0.05 mg/1 reduces the activities of sulphamethoxazole and trimethoprim and their combination in vitro. Using a biological assay procedure, levels of thymidine greater than this were interpreted as being present in urine. The addition of sulphamethoxazole and trimethoprim, singly or in combination, to urine obtained from patients with urinary tract infections showed that all the antibacterial effect towards sensitive organisms was due to the trimethoprim component. It is suggested that trimethoprim should replace the combination co-trimoxazole for the treatment of some lower urinary tract infections, and that laboratory media, if they are to resemble the clinical environment, should contain thymidine.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 344347      PMCID: PMC1145210          DOI: 10.1136/jcp.31.2.165

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  IMPROVED METHOD FOR THE ISOLATION OF THYMINE-REQUIRING MUTANTS OF ESCHERICHIA COLI.

Authors:  K A STACEY; E SIMSON
Journal:  J Bacteriol       Date:  1965-08       Impact factor: 3.490

2.  Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone.

Authors:  W H Inman
Journal:  Br Med J       Date:  1977-06-11

3.  Letter: Co-trimoxazole resistance.

Authors:  R Then; P Angehrn
Journal:  Br Med J       Date:  1974-01-12

4.  Characteristics of some co-trimoxazole-resistant Enterobacteriaceae from infected patients.

Authors:  J Barker; D Healing; J G Hutchison
Journal:  J Clin Pathol       Date:  1972-12       Impact factor: 3.411

5.  Thymine-requiring mutants of Proteus mirabilis selected by co-trimoxazole in vivo.

Authors:  O A Okubadejo; R M Maskell
Journal:  J Gen Microbiol       Date:  1973-08

6.  Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function.

Authors:  J Rieder; D E Schwartz; M Fernex; T Bergan; E K Brodwall; A Blumberg; P Cottier; W Scheitlin
Journal:  Antibiot Chemother (1971)       Date:  1974

7.  Letter: Is co-trimoxazole bactericidal in sputum?

Authors:  R W Lacey; E Lewis
Journal:  Br Med J       Date:  1973-10-20

8.  Activity and interaction of trimethoprim and sulphamethoxazole against Escherichia coli.

Authors:  D Greenwood; F O'Grady
Journal:  J Clin Pathol       Date:  1976-02       Impact factor: 3.411

9.  Thymine-requiring bacteria associated with co-trimoxazole therapy.

Authors:  R Maskell; O A Okubadejo; R H Payne
Journal:  Lancet       Date:  1976-04-17       Impact factor: 79.321

10.  Failure to demonstrate an advantage in combining sulphamethoxazole with trimethoprim in an experimental model of urinary infection.

Authors:  J D Anderson; R W Lacey; E L Lewis; M A Sellin
Journal:  J Clin Pathol       Date:  1974-08       Impact factor: 3.411

  10 in total
  19 in total

1.  Thymidine mutants.

Authors:  R Maskell; O A Okubadejo
Journal:  J Clin Pathol       Date:  1978-08       Impact factor: 3.411

2.  Synergistic antimicrobial activities of folic acid antagonists and nucleoside analogs.

Authors:  Johannes Zander; Silke Besier; Hanns Ackermann; Thomas A Wichelhaus
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

3.  General survey of trimethoprim combinations in the treatment of urinary tract infections.

Authors:  W Brumfitt; J M Hamilton-Miller
Journal:  Infection       Date:  1979       Impact factor: 3.553

4.  Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole?

Authors:  Asha C Bowen; Rachael A Lilliebridge; Steven Y C Tong; Robert W Baird; Peter Ward; Malcolm I McDonald; Bart J Currie; Jonathan R Carapetis
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

5.  Efficacy of trimethoprim in murine experimental infection with a thymidine kinase-deficient mutant of Escherichia coli.

Authors:  T Tokunaga; K Oka; A Takemoto; Y Ohtsubo; N Gotoh; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Bacterial resistance to trimethoprim.

Authors: 
Journal:  Br Med J       Date:  1980-08-30

Review 7.  Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

8.  Rifampin plus trimethoprim: bactericidal activity and suppression of resistance in human urine in vitro.

Authors:  B P Goldstein; I F Ripamonti; G Bolzoni; G Carniti; V Arioli
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

9.  Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate.

Authors:  S B Howell; S J Mansfield; R Taetle
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 10.  Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

Authors:  Mukesh Patel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.